A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus

Summary

To study once weekly injections of LY2189265 compared to placebo on blood glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 16 weeks in overweight Type 2 Diabetes Mellitus participants.

Timeline

Start

2008-04

Primary completion

2009-01

Completion

2009-01

Outcome

Met primary endpoint

registry analysis (superiority or other test); 1.0/2.0 Milligram (mg) LY2189265 vs Placebo; p <0.001; ANCOVA; NCT00630825 ↗

Drugs

Indications